Enhanced inflammasome activity in systemic lupus erythematosus is mediated via type I interferon upregulation of interferon regulatory factor 1

Conclusion: Prolonged type I IFN exposure, as seen in SLE patients, primes monocytes for robust inflammasome activation in an IRF1‐dependent manner. IRF1 inhibition may serve as a novel target for treatment of SLE‐associated inflammation and organ damage. This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fart.40166

Source: Arthritis and Rheumatism - May 31, 2017 Category: Rheumatology Authors: Jianhua Liu, Celine C. Berthier, J. Michelle Kahlenberg Tags: Full Length Source Type: research